Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 12, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $40.83 to $3,226,332.72.

Highlighted Stocks Traded by Insiders:

Insys Therapeutics (INSY) - FREE Research Report

Fourteau Patrick, who is Director at Insys Therapeutics, sold 10,000 shares at $59.94 on March 12, 2015. Following this transaction, the Director owned 70,000 shares meaning that the stake was reduced by 12.5% with the 10,000-share transaction.

The shares most recently traded at $61.25, up $1.31, or 2.15% since the insider transaction. Historical insider transactions for Insys Therapeutics go as follows:

  • 4-Week # shares bought: 16,500
  • 4-Week # shares sold: 25,000
  • 12-Week # shares bought: 16,500
  • 12-Week # shares sold: 25,000
  • 24-Week # shares bought: 16,500
  • 24-Week # shares sold: 25,000

The average volume for Insys Therapeutics has been 391,500 shares per day over the past 30 days. Insys Therapeutics has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are up 44.59% year-to-date as of the close of trading on Thursday.

Insys Therapeutics, Inc., a commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has a P/E ratio of 57.7. Currently, there are 4 analysts who rate Insys Therapeutics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on INSY - FREE

TheStreet Quant Ratings

rates Insys Therapeutics as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Insys Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Syntel (SYNT) - FREE Research Report

Reddy Murlidhar, who is Senior Vice President at Syntel, sold 1,600 shares at $50.26 on March 12, 2015. Following this transaction, the Senior Vice President owned 26,966 shares meaning that the stake was reduced by 5.6% with the 1,600-share transaction.

The shares most recently traded at $50.59, up $0.33, or 0.65% since the insider transaction. Historical insider transactions for Syntel go as follows:

  • 4-Week # shares sold: 2,600
  • 12-Week # shares sold: 2,600
  • 24-Week # shares sold: 6,739

The average volume for Syntel has been 150,400 shares per day over the past 30 days. Syntel has a market cap of $4.1 billion and is part of the technology sector and computer software & services industry. Shares are up 12.12% year-to-date as of the close of trading on Thursday.

Syntel, Inc. provides digital transformation, information technology (IT), and knowledge process outsourcing (KPO) services worldwide. The company operates through Banking and Financial Services; Healthcare and Life Sciences; Insurance; Retail, Logistics and Telecom; and Manufacturing segments. The company has a P/E ratio of 16.6. Currently, there are 5 analysts who rate Syntel a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SYNT - FREE

TheStreet Quant Ratings

rates Syntel as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Syntel Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

On Assignment (ASGN) - FREE Research Report

Callaghan Brian J., who is Director at On Assignment, sold 7,540 shares at $37.59 on March 12, 2015. Following this transaction, the Director owned 665,568 shares meaning that the stake was reduced by 1.12% with the 7,540-share transaction.

Sheridan Edwin A., who is Director at On Assignment, sold 10,900 shares at $37.59 on March 12, 2015. Following this transaction, the Director owned 1.7 million shares meaning that the stake was reduced by 0.63% with the 10,900-share transaction.

The shares most recently traded at $37.61, up $0.02, or 0.07% since the insider transaction. Historical insider transactions for On Assignment go as follows:

  • 4-Week # shares sold: 264,975
  • 12-Week # shares bought: 1,006
  • 12-Week # shares sold: 264,975
  • 24-Week # shares bought: 1,006
  • 24-Week # shares sold: 264,975

The average volume for On Assignment has been 374,100 shares per day over the past 30 days. On Assignment has a market cap of $1.9 billion and is part of the services sector and diversified services industry. Shares are up 14.7% year-to-date as of the close of trading on Thursday.

On Assignment, Inc. provides short- and long-term placement of contract, contract-to-hire, and direct hire professionals in the United States, Europe, Canada, Australia, and New Zealand. The company operates in four segments: Apex, Oxford, Physician, and Life Sciences Europe. The company has a P/E ratio of 25.3. Currently, there are 10 analysts who rate On Assignment a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASGN - FREE

TheStreet Quant Ratings

rates On Assignment as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, impressive record of earnings per share growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

On Assignment Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null